# EDGAR Filing Document

**Accession Number:** 0002025942
**File Stem:** 0001493152-25-011767
**Filing Date:** 2025-8
**Character Count:** 2693
**Document Hash:** 02175a08e010abfc67b7c5a1d772b6ae
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001493152-25-011767.hdr.sgml**: 20251216

**ACCESSION NUMBER**: 0001493152-25-011767

**CONFORMED SUBMISSION TYPE**: CORRESP

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20250808

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** Curanex Pharmaceuticals Inc
- **CENTRAL INDEX KEY:** 0002025942
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **ORGANIZATION NAME:** 03 Life Sciences
- **EIN:** 830741390
- **STATE OF INCORPORATION:** NV
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** CORRESP

**BUSINESS ADDRESS:**
- **STREET 1:** 2 JERICHO PLAZA,
- **STREET 2:** SUITE101B
- **CITY:** JERICHO
- **STATE:** NY
- **ZIP:** 11753
- **BUSINESS PHONE:** 718-673-6078

**MAIL ADDRESS:**
- **STREET 1:** 2 JERICHO PLAZA,
- **STREET 2:** SUITE101B
- **CITY:** JERICHO
- **STATE:** NY
- **ZIP:** 11753

Dominari Securities LLC

725 Fifth Avenue

New York NY 10022

**<u>VIA EDGAR</u>**

August 8, 2025

United States Securities and Exchange Commission

Division of Corporation Finance

100 F Street, N.E.

Washington, D.C. 20549

Re: Curanex Pharmaceuticals Inc. ("Company")

Registration Statement on Form S-1, as amended

File No. 333-282686

Ladies and Gentlemen:

Pursuant to Rule 461 under the Securities Act of 1933, as amended (the "Securities Act"), we, as the representative of the several underwriters of the Company's public offering, hereby join the Company's request that the effective date of the above-referenced Registration Statement be accelerated so that the above-referenced Registration Statement will be declared effective at 5:00 p.m., Eastern Time, on Tuesday, August 12, 2025, or as soon as practicable thereafter.

Pursuant to Rule 460 under the Securities Act, we, as the representative of the several underwriters, wish to advise you that there will be distributed to each Underwriter or dealer, who is reasonably anticipated to participate in the distribution of the securities, as many copies of the proposed form of preliminary prospectus as appears to be reasonable to secure adequate distribution of the preliminary prospectus.

We, the undersigned, as representatives of the several underwriters, have complied and will comply, and we have been informed by the participating underwriters that they have complied and will comply, with the requirements of Rule 15c2-8 under the Securities Exchange Act of 1934, as amended.

---

| | |
|:---|:---|
| Very truly yours, | Very truly yours, |
| DOMINARI SECURITIES LLC | DOMINARI SECURITIES LLC |
| */s/ Eric Newman* | */s/ Eric Newman* |
| Name: | Eric Newman |
| Title: | Executive Vice President, Head of Investment Banking |

---